Login to Your Account

Plenty More Behind Lead Drug

Sirion Series B Raises $45M For Phase III Ophthalmic Bid

By Randall Osborne

Tuesday, April 10, 2007
Ophthalmics-targeted Sirion Therapeutics Inc. pulled down $45 million in a Series B financing to boost a pipeline led by ST-601, the Phase III emulsion acquired last year for inflamed eyes. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription